Overview

Chemomab is a clinical-stage biotech company, focusing on discovery and development of innovative therapeutics for fibrosis-related diseases with large unmet need.

The company’s lead candidate, CM-101, is a first-in-class monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action.

Chemomab is currently promoting in parallel three phase 2 studies, focusing on the rare indications primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Recent News
Jan 4, 2022

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

Dec 20, 2021

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

Dec 16, 2021

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab) a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory...

Dec 3, 2021

Chemomab Therapeutics Ltd. (NASDAQ: CMMB), (Chemomab) a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases...

All News

Stock Info
NASDAQCMMB
Events
Monday, January 10, 2022 - Thursday, January 13, 2022
7:00am EST

Registration 

Presented Virtually

Senior management will present

Webcast on demand starting at 7:00am ET Jan.10, 2022 - Jan.13, 2022

Replay available at investors.chemomab.com/events starting on Jan.14, 2022

 

Wednesday, January 5, 2022 - Friday, January 7, 2022

Registration and 1x1 Meeting Requests

Presented Virtually

Senior management will participate

All Events

Featured Presentation

Chemomab Corporate Overview - January 2022

Download